A recent ruling against Johnson & Johnson and its McNeil PPC Inc. subsidiary in litigation about Children’s Motrin labeling further muddies the waters about OTC firms’ reliance on federal pre-emption against personal injury claims under state law.
The Massachusetts Supreme Judicial Court upheld a trial court’s verdict that McNeil/J&J could not claim that FDA regulatory history pre-empted its responsibility to warn about toxic epidermal necrolysis and Steven-Johnson Syndrome, skin disorders linked to the use of ibuprofen that caused a 7-year-old girl
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?